Nine ‐month results of the BIOHELIX‐I clinical trial study: Evaluation of the PRO‐Kinetic Energy cobalt chromium bare‐metal stent system

ConclusionsThe 9‐month TVF rate of the PKE stent was comparable to other BMS and is a viable option for treating CAD. The low observed rate of ischemia‐driven TVR supports the safety and efficacy of the novel BMS design.

Source: Catheterization and Cardiovascular Interventions - December 22, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Tesfaldet T. Michael, Gert Richardt, Alexandra Lansky, Robert J. Carney, Muhammad Akram Khan, Abbas Shehadeh, Uwe Zeymer, Saurabh Gupta Tags: CORONARY ARTERY DISEASE Source Type: research